[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diuretic-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diuretic-resistance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100532173","phase-1-mechanisms-of-diuretic-resistance-in-heart-failure-aim-3-100532173",false,"NCT06209359","Mechanisms of Diuretic Resistance in Heart Failure, Aim 3","MsDR Aim 3","Inclusion Criteria:\n\n* Clinical diagnosis of heart failure\n* No plan for titration\u002Fchange of heart failure medical or device therapies during the study period.\n* Absence of non-elective hospitalizations in the previous 2 months.\n* At optimal volume status by symptoms, exam, and dry weight.\n* Serum potassium ≤ 5.0 mmol\u002FL\n* Serum sodium ≥ 130 milliequivalents\u002F liter (mEq\u002FL)\n* Hemoglobin ≥8 g\u002FdL\n* Age \\>18 years\n* Objective evidence of diuretic resistance to a 10mg bumetanide challenge (screening visit may occur under this protocol or HIC2000032328 or HIC2000034315) defined as:\n\n  * FENa \\\u003C10% and total sodium output \\\u003C150mmol\n  * And at least one of the following criteria:\n\n    * Chronic home furosemide dose greater than or equal to 80mg furosemide equivalents\n    * eGFR \\\u003C 60ml\u002Fmin\n    * Serum chloride \\\u003C100mmol\u002FL\n    * FENa \\\u003C5% and total sodium output \\\u003C75mmol on the 2 hour\n\nExclusion Criteria:\n\n* Glomerular filtration rate (GFR) \\\u003C20 ml\u002Fmin\u002F1.73m2\n* Use of any non-loop type diuretic in the last 7 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone ≤50 mg)\n* History of flash pulmonary edema or a \"brittle\" volume sensitive HF phenotype such as amyloid cardiomyopathy\n* Hemoglobin \\\u003C 8 g\u002FdL\n* Pregnant or breastfeeding\n* Cirrhosis or known liver disease\n* History of metabolic or respiratory acidosis within 30 days\n* Use of metformin, acetazolamide, or any other agent that could predispose to acidosis\n* Patients who are on metformin may be enrolled if their metformin can be safely discontinued for the randomized treatment periods in each arm. Any participants who have consistently elevated blood glucose readings \\> 200 mg\u002FdL while inpatient will not be enrolled.\n* Serum bicarbonate level \\\u003C24mmol\u002FL at screening visit\n* Venous potential of hydrogen(pH) \\\u003C7.35 at screening visit\n* Inability to give written informed consent or comply with study protocol or follow-up visits\n* On Lithium therapy\n* On pimozide or thioridazine\n* Diagnosis of liver failure\n* Contraindications or allergy to sulfonamides\n* Any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Randomized double-blind placebo-controlled crossover study design",[26,27],"Heart Failure","Diuretic Resistance",[29,30,27],"Diuretic","Cardiomyopathy","RECRUITING","2026-05-18",{"date":34,"type":35},"2026-05-22","ACTUAL",{"date":37,"type":35},"2024-07-24",{"date":39,"type":20},"2029-03-01",{"name":41,"class":42},"Yale University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100599576","evaluation-of-the-efficacy-of-rhbnp-in-patients-with-diuretic-resistance-after-cardiac-surgery-100599576","NCT07086287","Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery","Evaluation of the Efficacy of Recombinant Human Brain Natriuretic Peptide in Patients With Diuretic Resistance After Cardiac Surgery: a Prospective Single-center Single-blind Randomized Controlled Study","rhBNP","Inclusion Criteria:\n\n* (1) Adult patients after cardiac surgery (age ≥ 18 years) (2) Fluid overload (3) Diuretic resistance Definition: Daily intravenous use of furosemide at a dose ≥ 80mg or equivalent doses of other diuretics, yet still unable to achieve an adequate urine output of 0.5\\~1.0mL\u002Fkg\u002Fh. Conversion formula for different loop diuretics: Oral furosemide 80mg = Intravenous furosemide 40mg = Oral\u002FIntravenous torsemide 20mg = Oral\u002FIntravenous bumetanide 1mg (4) Willing to participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Preoperative CKD patients undergo regular dialysis treatment; (2) Postoperative use of CRRT; (3) Drug allergies involved in this study; (4) Those with corrected systolic blood pressure still \\\u003C 90 mmHg after vasopressor use.",{"count":53,"type":20},120,[55],"NA","evaluation of the efficacy of recombinant human brain natriuretic peptide in patients with diuretic resistance after cardiac surgery: a prospective single-center single-blind randomized controlled study",[58,27],"After Cardiac Surgery",[60,61,62,63],"recombinant human brain natriuretic peptide","diuretic resistance","after cardiac surgery","the incidence of renal replacement therapy","NOT_YET_RECRUITING","2025-07-18",{"date":67,"type":35},"2025-07-25",{"date":69,"type":20},"2025-08-01",{"date":71,"type":20},"2028-06-30",{"name":73,"class":42},"The First Affiliated Hospital of Anhui Medical University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":83},"100529503","feasibility-study-to-support-cardiorenal-function-in-acute-decompensated-heart-failure-with-diuretic-resistance-100529503","NCT06174623","Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance","Early Feasibility Study to Mechanically Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance","Inclusion Criteria:\n\n1. Admitted to the hospital with a primary diagnosis of ADHF\n2. Clinical signs and\u002For symptoms of congestion defined as at least one of the following: dyspnea at rest or with minimal exertion, orthopnea, lower extremity edema (≥2+), elevated jugular venous pressure, pulmonary rales, pulmonary vascular congestion on chest x-ray, pleural effusion or ascites\n3. Projected need by the treating clinician for continued treatment with IV diuretic agents for more than 48 hours with the goal of significant fluid removal (more than 1L net fluid loss\u002F24h)\n4. Appropriate intravenous loop diuretic therapy at the time of enrollment, defined as at least the higher of:\n\n   1. Furosemide 40mg IV bid or equivalent\n   2. IV furosemide or equivalent IV loop diuretic equivalent to ≥2x the total oral daily loop diuretic dose at home in 2 divided doses\n5. Diuretic resistance defined as at least ONE of the following:\n\n   1. Urine output of less than 1.5L over 12h following the last diuretic dose, OR\n   2. Net fluid loss of less than 1L over the last 24 hours, OR\n   3. Spot urinary sodium concentration of less than 70 mmol\u002FL 2h following the last diuretic dose or cumulative 6-hour natriuresis of less than 100 mmol following the last diuretic dose, OR\n   4. Clinically unsatisfactory resolution of congestion\n6. Age ≥ 21 years old\n7. Signed informed consent\n\nExclusion Criteria:\n\n1. ADHF related to acute secondary disease (i.e., infection or acute coronary syndrome)\n2. Treatment with high dose inotropes (milrinone ≥0.375 mcg\u002Fkg\u002Fmin, dobutamine ≥5mcg\u002Fkg\u002Fmin or dopamine ≥5mcg\u002Fkg\u002Fmin) and\u002For treatment with vasopressors to maintain a systolic arterial blood pressure ≥90 mmHg or mean arterial blood pressure ≥60 mmHg\n3. Current or previous support with a durable left ventricular assist device (LVAD) at any time or use of an extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices, intra-aortic balloon pump or patient on home inotropes currently or within the last 30 days\n4. Recent myocardial infarction, percutaneous coronary intervention or surgical revascularization (within the last 30 days) or awaiting planned coronary intervention or surgery\n5. Fixed pulmonary vascular resistance of more than 5 Wood units, estimated PASP of more than 80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure\n6. Prior heart transplant, heart failure due to rejection of a previous heart transplant, or planned heart transplantation\n7. Reanimated cardiac arrest in the last 30 days\n8. Suspected or known amyloid disease or other restrictive cardiomyopathy\n9. Severe bleeding risk precluding anticoagulation:\n\n   1. Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 3 days\n   2. Gastrointestinal (GI) bleeding within 1 month requiring hospitalization and\u002For transfusion\n   3. Recent major surgery within 1 month if the surgical wound is judged to be associated with an increased risk of bleeding\n   4. Platelet count of less than 50,000 cells\u002Fmm3\n   5. Uncorrectable bleeding diathesis or coagulopathy\n10. Contraindicated anatomy:\n\n    1. Descending aortic anatomy that would prevent safe placement of the device (less than 18 mm or more than 28mm thoracoabdominal aorta diameter at deployment location)\n    2. Abnormalities of the aorta or subclavian or axillary arteries that would prevent safe device placement, including aneurysms, significant tortuosity, or calcifications\n    3. Axillary artery anatomy that would preclude safe placement of a 10F sheath including severe obstructive calcification or severe tortuosity\n    4. Iliofemoral artery anatomy that would preclude safe placement of a 16F introducer sheath including severe obstructive calcification or severe tortuosity\n    5. Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury\n    6. Prior endovascular surgery or percutaneous intervention involving the thoracoabdominal aorta or a subclavian\u002Faxillary artery or history of aortic dissection\n11. Severe aortic stenosis\n12. Known or suspected contrast induced nephropathy\n13. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with pre-medication\n14. Absolute contraindications or allergy to unfractionated heparin (e.g., heparin-induced thrombocytopenia) or device materials (e.g. nickel, titanium) that cannot be adequately treated with pre-medication\n15. Known hematologic diseases such as leukemia, any coagulopathy or hypercoagulable state, sickle cell anemia or thalassemia\n16. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:\n\n    1. Liver disease (cirrhosis of the liver \\[Child-Pugh class B or C\\]) or shock liver\n    2. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1\u002FFVC less than 0.7, and FEV1 less than 50% predicted\n    3. Prior kidney transplant, isolated single kidney, stage V Chronic Kidney Disease (eGFR ≤15) at admission OR use of dialysis, continuous renal replacement therapy (CRRT) or aquapheresis (ultrafiltration) in last 90 days\n17. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation\n18. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 90 days prior to the index procedure\n19. Active infection not controlled with antibiotic therapy\n20. Suspected or known pregnancy. Women of child-bearing age should have a negative pregnancy test.\n21. Body mass index (BMI) over 40 kg\u002Fm2\n22. Unable or unwilling to undergo screening, device implant and retrieval procedures, and 30-day follow-up\n23. Currently participating in an investigational drug or another device study that may influence the data collected for this study. Observational studies are not considered an exclusion\n24. Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject ability to give written informed consent and\u002For to comply with study procedures\n25. Active SARS-CoV-2 infection (Coronavirus-19 \\[COVID-19\\]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments","21 Years",{"count":83,"type":20},5,[55],"Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance",[26,87,88,89,90,91,27],"Acute Decompensated Heart Failure","Cardiorenal Syndrome","Heart Failure, Congestive","Heart Failure With Preserved Ejection Fraction","Heart Failure With Reduced Ejection Fraction",[93,94,95,96,97,98,99,100,101],"Puzzle Medical Devices","ModulHeart","Mechanical Circulatory Support","Intra-Aortic","MCS","LVAD","pVAD","percutaneous ventricular assist device","Left ventricular assist device","2024-06-13",{"date":104,"type":35},"2024-06-17",{"date":106,"type":20},"2024-08",{"date":108,"type":20},"2024-12",{"name":110,"class":111},"Puzzle Medical Devices Inc.","INDUSTRY"]